Quantcast

Latest Tyrosine kinase Stories

2014-03-26 08:29:12

Proceeds Will Advance Proprietary Biologic Product Candidates Targeting Receptor Tyrosine Kinases NEW HAVEN, Conn., March 26, 2014 /PRNewswire/ -- Kolltan Pharmaceuticals, a privately held biopharmaceutical company focused on the development of novel biologics targeting receptor tyrosine kinases, today announced the completion of a $60 million Series D financing. The financing was led by a new investor, a Boston-based global institutional asset manager, and by an existing investor,...

2014-03-10 08:30:35

BERGEN, Norway, March 10, 2014 /PRNewswire/ -- NOK 13 million funding secured from the Research Council of Norway BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key...

2014-03-04 08:31:11

SAN DIEGO, March 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014. Marcy Graham, Ambit's Executive Director of Investor Relations, will provide an overview of the Company...

2014-02-05 08:28:40

Accelerates development of BGB324, the only selective Axl kinase inhibitor in the clinic BERGEN, Norway, February 5, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013. Proceeds from the financing will be used to support the development...

2014-02-04 08:33:18

SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate,...

2014-01-30 04:21:54

- Trial Sponsored by Cardiff University and Supported by Cancer Research UK - SEATTLE, Jan. 30, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for...

2014-01-09 08:27:02

Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance BERGEN, Norway, January 9, 2014 /PRNewswire/ -- Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that preclinical data demonstrating that its lead compound, BGB324 has potential...

2014-01-07 13:48:44

Inhibitors of both JAK and Src kinases represent promising targets for cancer therapeutics because of the central importance of these kinases in tumor cell proliferation and survival. Furthermore, in cancer cells activation of JAK has been reported as a compensatory effect in response to Src inhibitor exposure. This implies simultaneous inhibition of both kinases could have a synergy of anti-cancer effects compared to an agent that inhibits one or the other kinases. The research article by...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.